<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577161</url>
  </required_header>
  <id_info>
    <org_study_id>PIX303</org_study_id>
    <nct_id>NCT00577161</nct_id>
  </id_info>
  <brief_title>Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL</brief_title>
  <official_title>Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CTI BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CTI BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced&#xD;
      delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent&#xD;
      has structural similarities to mitoxantrone as well as general similarities to anthracyclines&#xD;
      (such as the tricyclic central quinoid chromophore7).&#xD;
&#xD;
      This phase III study will compare the efficacy and safety of the combination BBR 2778,&#xD;
      fludarabine, and rituximab with the combination fludarabine and rituximab in patients with&#xD;
      relapsed or refractory indolent non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    closed to enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">September 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>day 64-71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate, survival, safety</measure>
    <time_frame>every 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fludarabine and rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fludarabine, rituximab, pixantrone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine and rituximab</intervention_name>
    <description>days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine, rituximab, pixantrone</intervention_name>
    <description>days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Histologically confirmed relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
          2. Any stage (Ann Arbor staging, Appendix 15.7), with or without B symptoms&#xD;
&#xD;
          3. CD 20+ lymphoma (confirmed by immunochemistry)&#xD;
&#xD;
          4. Measurable disease.&#xD;
&#xD;
          5. Atleast 1 prior therapy.&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. Life expectancy of at least 3 months&#xD;
&#xD;
          8. ECOG performance status (PS) of 0 or 1&#xD;
&#xD;
          9. Adequate cardiac function defined as LVEF ≥ 50% by MUGA scan&#xD;
&#xD;
         10. Adequate renal function&#xD;
&#xD;
         11. Adequate hepatic function&#xD;
&#xD;
         12. Adequate bone marrow function&#xD;
&#xD;
         13. Recovery from all acute toxicities from prior therapies (except alopecia and grade 1&#xD;
             peripheral neuropathy).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Prior treatment with a cumulative dose of doxorubicin equivalent exceeding 450 mg/m2&#xD;
&#xD;
          2. Radiotherapy, chemotherapy or other therapies for NHL within 4 weeks of treatment&#xD;
             start&#xD;
&#xD;
          3. Systemic corticosteroids to treat NHL within 5 days prior to first dose of study&#xD;
             treatment.&#xD;
&#xD;
          4. Radioimmunotherapy (RIT) within 3 months of treatment start&#xD;
&#xD;
          5. Known hypersensitivity to the excipients or the study drugs that the patient will&#xD;
             receive&#xD;
&#xD;
          6. Known Type I hypersensitivity or anaphylactic reactions to murine proteins or to any&#xD;
             component of rituximab&#xD;
&#xD;
          7. Major thoracic and/or abdominal surgery in the preceding 4 weeks, from which the&#xD;
             patient has not fully recovered (patients who have had minor surgery and one week's&#xD;
             recovery period may be enrolled)&#xD;
&#xD;
          8. HIV-related lymphoma&#xD;
&#xD;
          9. Active CNS involvement&#xD;
&#xD;
         10. Clinically significant cardiovascular abnormalities&#xD;
&#xD;
         11. Serious (NCI CTCAE grade 3-4) intercurrent infection at randomization, infection&#xD;
             requiring oral antibiotics, or deep-seated or systemic mycotic infections.&#xD;
&#xD;
         12. Investigational study drug within 30 days before randomization. Patient must have&#xD;
             recovered from all side effects of other investigational therapy.&#xD;
&#xD;
         13. Clinical symptoms suggesting unresolved HIV, HBV or HCV infection. .&#xD;
&#xD;
         14. History of another malignancy except: curatively treated basal cell or squamous cell&#xD;
             skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from&#xD;
             which the patient is currently in remission, or any other cancer from which the&#xD;
             patient has been disease-free for 5 years&#xD;
&#xD;
         15. Pregnant or lactating women&#xD;
&#xD;
         16. Potentially fertile men and women and their sexual partners not willing to use&#xD;
             adequate contraception as defined by the Investigator during the study and for 6&#xD;
             months after the last day of study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwest Alabama Cancer Center</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology Oncology Specialist</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol Comprehensive Cancer Care</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Hematology Oncology Associates</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interlakes Foundation, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Consultants</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Hematology Oncology, P.C.</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pixantrone</keyword>
  <keyword>NHL</keyword>
  <keyword>rituximab</keyword>
  <keyword>fludarabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Pixantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

